Tagrisso and Imfinzi are projected to generate global sales of $8bn and $7bn, respectively, by 2030, according to GlobalData.

Results from the Mariposa study found a regimen of Rybrevant and Lazcluze helped patients with a common form of advanced lung cancer live longer.

The Lazcluze plus Rybrevant combination could challenge AstraZeneca’s standard-of-care Tagrisso in non-small cell lung cancer ...

EGFR inhibitors like AstraZeneca's Tagrisso have been hugely successful in treating EGFR-positive lung cancer, but the durability of treatment is often reduced by resistance mutations. Now ...

Osimertinib, also known as Tagrisso and made by AstraZeneca, can help stop cancer from returning after surgery ...

UK pharma major AstraZeneca today revealed that, this week, it has received two positive recommendations from the National ...

AstraZeneca has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for ...

Patients on Tagrisso had less than half the risk of progression or death compared with patients on Tarceva or Iressa: the median PFS was 18.9 months for patients on Tagrisso vs.10.2 months for ...

AstraZeneca (AZ) has received two separate recommendations from the National Institute for Health and Care Excellence (NICE) for use of its lung cancer drugs Tagrisso (osimertinib) and Imfinzi ...

The drug was previously available through the Cancer Drugs Fund, but with more data, NICE is backing routine access through the NHS.

First-line Rybrevant plus Lazcluze improved survival versus the current standard of care in patients with mutated advanced or metastatic NSCLC.

Chinese regulators have accepted HUTCHMED's (NASDAQ:HCM) application for priority review for the drug combination Orpathys and Tagrisso in the treatment of certain patients with EGFR-positive non ...